MINNEAPOLIS--(BUSINESS WIRE)--Results from the largest U.S. outpatient heart failure clinical study, published today in the journal Circulation and funded by Medtronic, Inc. (NYSE: MDT), demonstrate that select guideline-based outpatient heart failure process measures positively impact patient survival and may be useful for assessing and improving overall patient quality of care. Findings from IMPROVE HF (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), showed that most of the Class IA heart failure therapies measured, including implantable defibrillator therapy and cardiac resynchronization therapy, were linked to a lower risk of mortality. Specifically, compliance with the implantable cardioverter defibrillator (ICD) process measure in eligible patients was associated with 38 percent lower odds of mortality over two years, and cardiac resynchronization therapy (CRT) process measure compliance was associated with 36 percent lower odds of mortality.
